Accelerating Novel ADC Development through WuXi XDC’s Innovative Technology & Integrated Development/Manufacturing Platform
Time: 5:30 pm
day: Day One PM
Details:
- Learning how 5 of 13 approved ADCs use random cysteine conjugation with MMAE, capped at 2 mg/kg to avoid TEAEs
- Discussing how WuXiDAR4's proprietary technology creates ADCs with a narrowly distributed DAR for enhanced efficacy and safety, eliminating the need to modify monoclonal antibodies or any enzymes, simplifying the process and reducing costs of goods
- Outlining how WuXi XDC CDMO platform integrates the development and manufacturing of monoclonal antibody intermediates, payload linkers, conjugation, and drug products, expediting development from DNA to IND in under 15 months with over 60 successful IND submissions
- Leveraging deep expertise and comprehensive manufacturing, WuXi XDC offers a clear strategy to secure successful BLA filings for its clients
